U.S. Food and Drug Administration Approves POMALYST® (pomalidomide) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

View Full Size 

Download

• Full Size JPEG, 1600x1000, 206.2 KB
• Small JPEG, 300x187, 22.5 KB
• Preview JPEG, 144x90, 7.2 KB
• Thumbnail JPEG, 112x70, 5.1 KB